GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742
                                 
                                                         
                            
                            
                            
                                 
                                
                                galcanezumab is an approved drug (FDA (2018)) 
                                                        
                                                    
                                Compound class: 
                                                            Antibody
                                 
                                
                                    
                                        Comment: Galcanezumab (LY2951742) is a monoclonal antibody targeting calcitonin A and B (CALCA a.k.a. α-CGRP and CALCB a.k.a. β-CGRP respectively), whose anti-migraine and analgesic actions can be applied clinically.  
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                    Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent WO2007076336 [1].  | 
                                    
| Bioactivity Comments | 
| A Fab fragment of the antibody binds human αCGRP with a Kd of 2.09nM and the β isoform with a Kd of 1.22nM [1]. | 
| Selectivity at ligand targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
                                                                        
                                                                         
  | 
                                                                |||||||||||||||||||||||||||||||||||||||||||||||||||||||